Sign in →

Test Code THROMB DNA Thrombosis Risk DNA Panel

Clinical System Name

Thrombosis DNA Panel

Description

The panel includes simultaneous testing for the factor V Leiden mutation in the F5 gene & the prothrombin variant c.20210G>A in the F2 gene.  This test is indicated for individuals with a history of venous thromboembolism (VTE) as part of thrombophilia work up.  

Sample Requirements

Specimen: Whole blood

Container(s): Lavender/EDTA, Yellow/ACD A or B
Preferred Vol: 5mL (for Adult) 3 mL (Child)

Minimum Vol: 1 mL

  

Specimen: Buccal Swab

Container(s): Buccal Swab

Preferred Vol: 4-6 swabs

Minimum Vol: 2 swabs

Note:  Accepted for bone marrow transplant patients.  Swabs available from Send Out Lab, 987-2563.

Processing Instructions

Reject due to: Heparin

Spin: No

Aliquot: No

Temp: Refrigerate

Storage location: CPA refrigerator sendouts rack

Stability

Specimen Type Temperature Time
Whole blood Room temp 3 days
Whole blood Refrigerated 7 days
Buccal swab Refrigerated 1 day

 

Availability

STAT Performed TAT
Contact lab Weekly 1 week

 

Performing Laboratory

University of Washington

Dept of Laboratory Medicine

UW Genetics Lab

1959 NE Pacific St, NW220
Seattle, WA 98195
 

Phone Number: (206) 520-4600

Department

Department: Send Outs

 

Phone Number: (206) 987-2563

Reference Range

Interpretive report will be provided

Methodology

Method: PCR

CPT Codes

81241

81240

Clinical Utility

The panel includes simultaneous testing for the factor V Leiden mutation in the F5 gene & the prothrombin variant c.20210G>A in the F2 gene.  This test is indicated for individuals with a history of venous thromboembolism (VTE) as part of thrombophilia work up.  

 

The factor V Leiden mutation is the most common cause of activated protein C (APC) resistance, and most common genetic risk factor for thrombosis. Approximately 3-8% of the population is heterozygous, and have an estimated 5-10 fold increased risk of thrombosis. Homozygotes have a 50-100 fold increased risk.

The common prothrombin c.20210G>A variant is associated with elevated prothrombin levels, which promotes development of fibrin clots. 2-4 % of the population is heterozygous for PTV 20210. Heterozygotes have an estimated 3-11 fold increased risk of thrombosis.

Send Out Instructions

 

Reference Test Name: Thrombophilia DNA Screen
Reference Test Number: TPDS
Instructions: Send out M - F with the UW courier.

 

Related Tests